No Data
No Data
Needham Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $41
Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham
Insider Sale: Chief Technology Officer of $RNAC (RNAC) Sells 32,789 Shares
Timothy Springer Bought 4.9% More Shares In Cartesian Therapeutics
Cartesian Therapeutics(RNAC.US) 10% Shareholder Buys US$7.37 Million in Common Stock
Yale University's Strategic Bet on Cartesian Therapeutics Skyrockets in Q3 2024
No Data
No Data